Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Gains from Investment Securities (2022)

Historic Gains from Investment Securities for Northwest Biotherapeutics (NWBO) over the last 4 years, with Q3 2022 value amounting to $304.6 million.

  • Northwest Biotherapeutics' Gains from Investment Securities changed N/A to $304.6 million in Q3 2022 from the same period last year, while for Dec 2024 it was -$45.7 million, marking a year-over-year change of. This contributed to the annual value of $364000.0 for FY2024, which is N/A changed from last year.
  • Northwest Biotherapeutics' Gains from Investment Securities amounted to $304.6 million in Q3 2022.
  • Over the past 5 years, Northwest Biotherapeutics' Gains from Investment Securities peaked at $304.6 million during Q3 2022, and registered a low of $304.6 million during Q3 2022.